Barclays’s Anixa Biosciences ANIX Stock Holding History

Barclays’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$608	Buy	+217	New	+$603	﹤0.01%	4976
2025 Q4	–	Sell	-9	Closed	-$30	–	5219
2025 Q3	$30	Buy	+9	New	+$28	﹤0.01%	5338
2021 Q3	–	Sell	-2,532	Closed	-$10K	–	4733
2021 Q2	$10K	Sell	2,532 -7,466	-75%	-$31.8K	﹤0.01%	4621
2021 Q1	$47K	Buy	+9,998	New	+$47.8K	﹤0.01%	4211
2020 Q1	–	Sell	-1	Closed	–	–	6113
2019 Q4	$0	Buy	+1	New	+$4	﹤0.01%	6316
2018 Q2	–	Sell	-15	Closed	–	–	6941
2018 Q1	$0	Buy	+15	New	+$58	﹤0.01%	7023

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Barclays's ANIX Position: Q2 2026 in Review

Barclays opened a new position in Anixa Biosciences (ANIX) in Q2 2026: 217 shares worth $608. The stake represents ﹤0.01% of the portfolio and ranks #4976 among its holdings. This is a return to the name: Barclays previously reported a position in ANIX as recently as Q3 2025.

Barclays first reported a position in ANIX in Q1 2018 and has held it in 6 quarters since. The position peaked at $47K in Q1 2021. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

Barclays held 217 shares of Anixa Biosciences worth $608 as of Q2 2026.
Anixa Biosciences was a new Barclays position in Q2 2026.
Anixa Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4976 holding.
Barclays first reported a position in Anixa Biosciences in Q1 2018 and has held it in 6 quarters since.
Barclays's Anixa Biosciences position peaked at $47K in Q1 2021.
63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.